Prevention of Reperfusion Injury Outcomes Through Effective Cardioprotection Targeting Myocardial Infarction

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 300 participants.

Also called NCT07362446

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 300 participants (planned count) (from the registry)
Sponsor
Nyrada Pty Ltd (from the registry)
Registry
  • NCT NCT07362446
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Australia (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07362446. Randomized; quadruple masking; primary purpose treatment. Start 2026-07-02 (actual); primary completion 2027-06-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Prevention of Reperfusion Injury Outcomes Through Effective Cardioprotection Targeting Myocardial Infarction
Acronym
PROTECT-MI
Condition
Reperfusion Injury
Condition
AMI
Condition
STEMI (ST Elevation MI)
Intervention (Drug)
Xolatryp
Intervention (Drug)
Placebo
Lead sponsor
Nyrada Pty Ltd (class: industry)

Record details

Record id
cardio:ct-nct07362446
Content hash
2636d91d38d1f3ba314a81868708ea3f4add9e156c2ae6a3068fe48faf3a395b